Found: 143
Select item for more details and to access through your institution.
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 5, p. 1472, doi. 10.1007/s10637-020-00916-3
- By:
- Publication type:
- Article
Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 5, p. 795, doi. 10.1007/s10637-014-0102-9
- By:
- Publication type:
- Article
Array-CGH predicts prognosis in plasma cell post-transplantation lymphoproliferative disorders.
- Published in:
- Genes, Chromosomes & Cancer, 2017, v. 56, n. 3, p. 221, doi. 10.1002/gcc.22428
- By:
- Publication type:
- Article
Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma.
- Published in:
- Genes, Chromosomes & Cancer, 2016, v. 55, n. 3, p. 251, doi. 10.1002/gcc.22328
- By:
- Publication type:
- Article
Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin's lymphoma.
- Published in:
- Genes, Chromosomes & Cancer, 2007, v. 46, n. 5, p. 500, doi. 10.1002/gcc.20436
- By:
- Publication type:
- Article
Expression of genes coding for the tumor necrosis factor and lymphotoxin ligand-receptor system in non-Hodgkin's lymphomas.
- Published in:
- Cancer Immunology, Immunotherapy, 2000, v. 49, n. 9, p. 469, doi. 10.1007/s002620000127
- By:
- Publication type:
- Article
Normal B cells express ZAP70 in chronic lymphocytic leukemia: A link between autoimmunity and lymphoproliferation?
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 1, p. 48, doi. 10.1002/ajh.27137
- By:
- Publication type:
- Article
Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA‐1, and TRANSCEND trials.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 10, p. 1295, doi. 10.1002/ajh.26301
- By:
- Publication type:
- Article
Relapsed/Refractory International Prognostic Index (R/R‐IPI): An international prognostic calculator for relapsed/refractory diffuse large B‐cell lymphoma.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 5, p. 599, doi. 10.1002/ajh.26149
- By:
- Publication type:
- Article
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 5, p. 510, doi. 10.1002/ajh.25757
- By:
- Publication type:
- Article
Long‐term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP‐ritux.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 12, p. 1314, doi. 10.1002/ajh.25632
- By:
- Publication type:
- Article
Early‐onset severe infections in allogeneic hematopoietic stem cell transplantation recipients with graft failure.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 4, p. E109, doi. 10.1002/ajh.25406
- By:
- Publication type:
- Article
Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC-based first-line treatment: Retrospective observations from the FILO group.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 1, p. E24, doi. 10.1002/ajh.24951
- By:
- Publication type:
- Article
BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 6, p. 515, doi. 10.1002/ajh.24701
- By:
- Publication type:
- Article
Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.
- Published in:
- American Journal of Hematology, 2016, v. 91, p. 410, doi. 10.1002/ajh.24305
- By:
- Publication type:
- Article
Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 4, p. 410, doi. 10.1002/ajh.24305
- By:
- Publication type:
- Article
Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines.
- Published in:
- Scientific Reports, 2015, p. 8068, doi. 10.1038/srep08068
- By:
- Publication type:
- Article
Treatment with Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) with Acute Myeloid Leukemia: A Single Institution Experience.
- Published in:
- Mediterranean Journal of Hematology & Infectious Diseases, 2016, v. 8, p. 1, doi. 10.4084/MJHID.2016.009
- By:
- Publication type:
- Article
CD180 overexpression in follicular lymphoma is restricted to the lymph node compartment.
- Published in:
- Cytometry. Part B, 2016, v. 90, n. 5, p. 433, doi. 10.1002/cyto.b.21331
- By:
- Publication type:
- Article
Successful pregnancies in patients with BCR‐ABL‐positive leukemias treated with interferon‐alpha therapy during the tyrosine kinase inhibitors era.
- Published in:
- European Journal of Haematology, 2018, v. 101, n. 6, p. 774, doi. 10.1111/ejh.13167
- By:
- Publication type:
- Article
Acute myeloid leukemia in the elderly (age 70 yr or older): long-term survivors.
- Published in:
- European Journal of Haematology, 2017, v. 98, n. 2, p. 134, doi. 10.1111/ejh.12811
- By:
- Publication type:
- Article
Biomarkers and Prognosis in Malignant Lymphomas.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, n. 2, p. 160
- By:
- Publication type:
- Article
Epstein-Barr Virus–Induced Lymphoproliferative Disorder After Rituximab Combined with CHOP Therapy.
- Published in:
- Clinical Lymphoma & Myeloma, 2008, v. 8, n. 6, p. 356
- By:
- Publication type:
- Article
Prevalence of Anticentromere F Protein Autoantibodies in 347 Patients with Non-Hodgkin's Lymphoma.
- Published in:
- Annals of the New York Academy of Sciences, 2005, v. 1050, n. 1, p. 319, doi. 10.1196/annals.1313.034
- By:
- Publication type:
- Article
Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1.
- Published in:
- Oncology & Therapy, 2019, v. 7, n. 2, p. 121, doi. 10.1007/s40487-019-0095-9
- By:
- Publication type:
- Article
Bone Marrow Necrosis in Newly Diagnosed Acute Leukemia: Two Case Reports and Review of the Literature.
- Published in:
- Oncology & Therapy, 2017, v. 5, n. 1, p. 111, doi. 10.1007/s40487-017-0041-7
- By:
- Publication type:
- Article
Ibrutinib-Induced Lymphocytosis: Cytological Features.
- Published in:
- Acta Haematologica, 2017, v. 137, n. 1, p. 55, doi. 10.1159/000452437
- By:
- Publication type:
- Article
What Does This Mutation Mean? The Tools and Pitfalls of Variant Interpretation in Lymphoid Malignancies.
- Published in:
- International Journal of Molecular Sciences, 2018, v. 19, n. 4, p. 1251, doi. 10.3390/ijms19041251
- By:
- Publication type:
- Article
Distinct chromosome 3 abnormalities in persistent polyclonal B-cell lymphocytosis.
- Published in:
- Genes, Chromosomes & Cancer, 1999, v. 26, n. 3, p. 221, doi. 10.1002/(SICI)1098-2264(199911)26:3<221::AID-GCC6>3.0.CO;2-9
- By:
- Publication type:
- Article
Improving Cancer Patient Care with Combined Medication Error Reviews and Morbidity and Mortality Conferences.
- Published in:
- Chemotherapy (0009-3157), 2014, v. 59, n. 5, p. 330, doi. 10.1159/000358190
- By:
- Publication type:
- Article
Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2011, v. 103, n. 23, p. 1799, doi. 10.1093/jnci/djr418
- By:
- Publication type:
- Article
One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.
- Published in:
- Frontiers in Immunology, 2018, p. 1, doi. 10.3389/fimmu.2018.00704
- By:
- Publication type:
- Article
Factors Affecting the Clinical Course of Follicular Lymphoma: A Multistate Survival Analysis Using Individual Patient Data from Eight Multicenter Randomized Clinical Trials.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 11, p. e1009, doi. 10.1016/j.clml.2022.07.015
- By:
- Publication type:
- Article
ABCL-346: Overall Survival with Tafasitamab + Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S392, doi. 10.1016/S2152-2650(21)01891-7
- By:
- Publication type:
- Article
Poster: ABCL-346: Overall Survival with Tafasitamab + Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S239, doi. 10.1016/S2152-2650(21)01499-3
- By:
- Publication type:
- Article
BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S251, doi. 10.1016/j.clml.2019.07.158
- By:
- Publication type:
- Article
Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Elderly Patients (Age 70 Years or Older) With Secondary Acute Myeloid Leukemia or Acute Myeloid Leukemia Developed Concurrently to Another Malignant Disease.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S380, doi. 10.1016/j.clml.2017.07.227
- By:
- Publication type:
- Article
Targeting netrin-1/ DCC interaction in diffuse large B-cell and mantle cell lymphomas.
- Published in:
- EMBO Molecular Medicine, 2016, v. 8, n. 2, p. 96, doi. 10.15252/emmm.201505480
- By:
- Publication type:
- Article
Pretreatment Levels of Vascular Endothelial Growth Factor in Plasma Predict a Complete Remission Rate and Time to Relapse or Progression in Patients with Diffuse Large B-Cell Lymphoma.
- Published in:
- Archivum Immunologiae & Therapiae Experimentalis, 2013, v. 61, n. 2, p. 165, doi. 10.1007/s00005-012-0215-9
- By:
- Publication type:
- Article
Plasma TNF-α and IL-10 Level-Based Prognostic Model Predicts Outcome of Patients with Diffuse Large B-Cell Lymphoma in Different Risk Groups Defined by the International Prognostic Index.
- Published in:
- Archivum Immunologiae & Therapiae Experimentalis, 2010, v. 58, n. 2, p. 131, doi. 10.1007/s00005-010-0066-1
- By:
- Publication type:
- Article
Two new miR-16 targets: caprin-1 and HMGA1, proteins implicated in cell proliferation.
- Published in:
- Biology of the Cell (Wiley-Blackwell), 2009, v. 101, n. 10, p. 511, doi. 10.1042/BC20080213
- By:
- Publication type:
- Article
Impact of rituximab on stem cell mobilization following ACVBP regimen in poor-risk patients with diffuse large B-cell lymphoma: results from a large cohort of patients.
- Published in:
- Transfusion, 2013, v. 53, n. 1, p. 115, doi. 10.1111/j.1537-2995.2012.03683.x
- By:
- Publication type:
- Article
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 5, p. 1938, doi. 10.1007/s12325-024-02822-z
- By:
- Publication type:
- Article
Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1.
- Published in:
- 2021
- By:
- Publication type:
- journal article